Login to Your Account



BioCryst, Mundipharma Enter Deal Potentially Worth $190M

By Jennifer Boggs


Friday, February 3, 2006
BioCryst Pharmaceuticals Inc. is expanding development and marketing for its lead product, Fodosine, through a potential $190 million oncology deal with Mundipharma International Holdings Ltd. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription